Cargando…

Pulmonary vein isolation plus left atrial posterior wall isolation and additional nonpulmonary vein trigger ablation using high‐dose isoproterenol for long‐standing persistent atrial fibrillation

BACKGROUND: Little evidence exists regarding the endpoint and optimum approach to catheter ablation for long‐standing persistent atrial fibrillation (LSPAF). We examined the efficacy of pulmonary vein isolation (PVI) plus left atrium posterior wall isolation (PWI) and additional non‐PV trigger ablat...

Descripción completa

Detalles Bibliográficos
Autores principales: Takamiya, Tomomasa, Nitta, Junichi, Sato, Akira, Inamura, Yukihiro, Kato, Nobutaka, Inaba, Osamu, Negi, Ken, Yamato, Tsunehiro, Matsumura, Yutaka, Takahashi, Yoshihide, Goya, Masahiko, Hirao, Kenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457393/
https://www.ncbi.nlm.nih.gov/pubmed/31007785
http://dx.doi.org/10.1002/joa3.12168
_version_ 1783409895659274240
author Takamiya, Tomomasa
Nitta, Junichi
Sato, Akira
Inamura, Yukihiro
Kato, Nobutaka
Inaba, Osamu
Negi, Ken
Yamato, Tsunehiro
Matsumura, Yutaka
Takahashi, Yoshihide
Goya, Masahiko
Hirao, Kenzo
author_facet Takamiya, Tomomasa
Nitta, Junichi
Sato, Akira
Inamura, Yukihiro
Kato, Nobutaka
Inaba, Osamu
Negi, Ken
Yamato, Tsunehiro
Matsumura, Yutaka
Takahashi, Yoshihide
Goya, Masahiko
Hirao, Kenzo
author_sort Takamiya, Tomomasa
collection PubMed
description BACKGROUND: Little evidence exists regarding the endpoint and optimum approach to catheter ablation for long‐standing persistent atrial fibrillation (LSPAF). We examined the efficacy of pulmonary vein isolation (PVI) plus left atrium posterior wall isolation (PWI) and additional non‐PV trigger ablation using high‐dose isoproterenol for LSPAF. METHODS: One‐hundred and fifty‐five patients (median AF duration, 36 months) underwent catheter ablation for LSPAF; After PVI plus PWI, they underwent provocation of non‐PV triggers by high‐dose isoproterenol and were divided into 3 groups based on the results: group A, PVI plus PWI alone, without induced non‐PV triggers (single procedure: 105 patients, multiple procedures: 90 patients); group B, mappable non‐PV triggers demonstrated and ablated (single procedure: 41 patients, multiple procedures: 45 patients); group C, if non‐PV triggers were unmappable or could not be induced in repeated procedures, adjunctive complex fractionated atrial electrogram ablation was performed (single procedure: 9 patients, multiple procedures: 20 patients). RESULTS: The Kaplan‐Meier estimate of the 1‐year freedom from atrial tachyarrhythmias without antiarrhythmic drugs was 65% in all patients, (73%, 56%, and 11% in groups A, B, and C, respectively) after a single procedure, which improved to 86% in all patients (93%, 86%, and 53% in groups A, B, and C, respectively) after multiple procedures. CONCLUSION: Even for LSPAF, in approximately 60% of patients, non‐PV triggers were not elicited, and PVI plus PWI alone achieved good outcomes. Although the inducibility of non‐PV triggers was associated with recurrence of atrial tachyarrhythmias, additional non‐PV trigger ablation may improve the outcome after multiple procedures.
format Online
Article
Text
id pubmed-6457393
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-64573932019-04-19 Pulmonary vein isolation plus left atrial posterior wall isolation and additional nonpulmonary vein trigger ablation using high‐dose isoproterenol for long‐standing persistent atrial fibrillation Takamiya, Tomomasa Nitta, Junichi Sato, Akira Inamura, Yukihiro Kato, Nobutaka Inaba, Osamu Negi, Ken Yamato, Tsunehiro Matsumura, Yutaka Takahashi, Yoshihide Goya, Masahiko Hirao, Kenzo J Arrhythm Original Articles BACKGROUND: Little evidence exists regarding the endpoint and optimum approach to catheter ablation for long‐standing persistent atrial fibrillation (LSPAF). We examined the efficacy of pulmonary vein isolation (PVI) plus left atrium posterior wall isolation (PWI) and additional non‐PV trigger ablation using high‐dose isoproterenol for LSPAF. METHODS: One‐hundred and fifty‐five patients (median AF duration, 36 months) underwent catheter ablation for LSPAF; After PVI plus PWI, they underwent provocation of non‐PV triggers by high‐dose isoproterenol and were divided into 3 groups based on the results: group A, PVI plus PWI alone, without induced non‐PV triggers (single procedure: 105 patients, multiple procedures: 90 patients); group B, mappable non‐PV triggers demonstrated and ablated (single procedure: 41 patients, multiple procedures: 45 patients); group C, if non‐PV triggers were unmappable or could not be induced in repeated procedures, adjunctive complex fractionated atrial electrogram ablation was performed (single procedure: 9 patients, multiple procedures: 20 patients). RESULTS: The Kaplan‐Meier estimate of the 1‐year freedom from atrial tachyarrhythmias without antiarrhythmic drugs was 65% in all patients, (73%, 56%, and 11% in groups A, B, and C, respectively) after a single procedure, which improved to 86% in all patients (93%, 86%, and 53% in groups A, B, and C, respectively) after multiple procedures. CONCLUSION: Even for LSPAF, in approximately 60% of patients, non‐PV triggers were not elicited, and PVI plus PWI alone achieved good outcomes. Although the inducibility of non‐PV triggers was associated with recurrence of atrial tachyarrhythmias, additional non‐PV trigger ablation may improve the outcome after multiple procedures. John Wiley and Sons Inc. 2019-02-18 /pmc/articles/PMC6457393/ /pubmed/31007785 http://dx.doi.org/10.1002/joa3.12168 Text en © 2019 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Takamiya, Tomomasa
Nitta, Junichi
Sato, Akira
Inamura, Yukihiro
Kato, Nobutaka
Inaba, Osamu
Negi, Ken
Yamato, Tsunehiro
Matsumura, Yutaka
Takahashi, Yoshihide
Goya, Masahiko
Hirao, Kenzo
Pulmonary vein isolation plus left atrial posterior wall isolation and additional nonpulmonary vein trigger ablation using high‐dose isoproterenol for long‐standing persistent atrial fibrillation
title Pulmonary vein isolation plus left atrial posterior wall isolation and additional nonpulmonary vein trigger ablation using high‐dose isoproterenol for long‐standing persistent atrial fibrillation
title_full Pulmonary vein isolation plus left atrial posterior wall isolation and additional nonpulmonary vein trigger ablation using high‐dose isoproterenol for long‐standing persistent atrial fibrillation
title_fullStr Pulmonary vein isolation plus left atrial posterior wall isolation and additional nonpulmonary vein trigger ablation using high‐dose isoproterenol for long‐standing persistent atrial fibrillation
title_full_unstemmed Pulmonary vein isolation plus left atrial posterior wall isolation and additional nonpulmonary vein trigger ablation using high‐dose isoproterenol for long‐standing persistent atrial fibrillation
title_short Pulmonary vein isolation plus left atrial posterior wall isolation and additional nonpulmonary vein trigger ablation using high‐dose isoproterenol for long‐standing persistent atrial fibrillation
title_sort pulmonary vein isolation plus left atrial posterior wall isolation and additional nonpulmonary vein trigger ablation using high‐dose isoproterenol for long‐standing persistent atrial fibrillation
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457393/
https://www.ncbi.nlm.nih.gov/pubmed/31007785
http://dx.doi.org/10.1002/joa3.12168
work_keys_str_mv AT takamiyatomomasa pulmonaryveinisolationplusleftatrialposteriorwallisolationandadditionalnonpulmonaryveintriggerablationusinghighdoseisoproterenolforlongstandingpersistentatrialfibrillation
AT nittajunichi pulmonaryveinisolationplusleftatrialposteriorwallisolationandadditionalnonpulmonaryveintriggerablationusinghighdoseisoproterenolforlongstandingpersistentatrialfibrillation
AT satoakira pulmonaryveinisolationplusleftatrialposteriorwallisolationandadditionalnonpulmonaryveintriggerablationusinghighdoseisoproterenolforlongstandingpersistentatrialfibrillation
AT inamurayukihiro pulmonaryveinisolationplusleftatrialposteriorwallisolationandadditionalnonpulmonaryveintriggerablationusinghighdoseisoproterenolforlongstandingpersistentatrialfibrillation
AT katonobutaka pulmonaryveinisolationplusleftatrialposteriorwallisolationandadditionalnonpulmonaryveintriggerablationusinghighdoseisoproterenolforlongstandingpersistentatrialfibrillation
AT inabaosamu pulmonaryveinisolationplusleftatrialposteriorwallisolationandadditionalnonpulmonaryveintriggerablationusinghighdoseisoproterenolforlongstandingpersistentatrialfibrillation
AT negiken pulmonaryveinisolationplusleftatrialposteriorwallisolationandadditionalnonpulmonaryveintriggerablationusinghighdoseisoproterenolforlongstandingpersistentatrialfibrillation
AT yamatotsunehiro pulmonaryveinisolationplusleftatrialposteriorwallisolationandadditionalnonpulmonaryveintriggerablationusinghighdoseisoproterenolforlongstandingpersistentatrialfibrillation
AT matsumurayutaka pulmonaryveinisolationplusleftatrialposteriorwallisolationandadditionalnonpulmonaryveintriggerablationusinghighdoseisoproterenolforlongstandingpersistentatrialfibrillation
AT takahashiyoshihide pulmonaryveinisolationplusleftatrialposteriorwallisolationandadditionalnonpulmonaryveintriggerablationusinghighdoseisoproterenolforlongstandingpersistentatrialfibrillation
AT goyamasahiko pulmonaryveinisolationplusleftatrialposteriorwallisolationandadditionalnonpulmonaryveintriggerablationusinghighdoseisoproterenolforlongstandingpersistentatrialfibrillation
AT hiraokenzo pulmonaryveinisolationplusleftatrialposteriorwallisolationandadditionalnonpulmonaryveintriggerablationusinghighdoseisoproterenolforlongstandingpersistentatrialfibrillation